title: The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2(High) receptors.
abstract: Dopaminergic stabilizers are recognized as compounds that can either enhance or antagonize dopamine (DA)-dependent behaviors depending on the prevailing dopaminergic tone. The dopaminergic stabilizer ASP2314 is being tested clinically and has been reported to have antipsychotic effects in a clinical trial as an add on medication. To elucidate the mechanisms of action of this dopaminergic stabilizer, its potency on the functional dopamine D2(High) receptors was examined. In competition with D2 receptors selectively labeled by [3H]domperidone, ASP2314 had a dissociation constant, Ki(High), of 1.62 microM for D2(High) in human cloned D2Long receptors and 0.83 muM for rat homogenized striata. Using the D2 agonist ligand [3H](+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol ((+)PHNO), ASP2314 had a high-affinity Ki of 32 nM for D2(High) for rat homogenized striata. ASP2314 stimulated the incorporation of [35S]GTP-gamma-S into rat striata by 50% at 43 nM, and into the cloned D2Long membranes by 50% at 3.2 microM (compared to 100% stimulation by 10 microM dopamine). With similar concentrations of ASP2314 inhibiting the binding of ligands at D2(High) and stimulating [35S]GTP-gamma-S incorporation, the data indicate that the dopaminergic stabilizing action of ASP2314 may be related to the selectivity for the D2(high) state of the D2 receptor.
authors: Clera Inc., 260 Heath Street West, Toronto, Ontario, Canada M5P 3L6. phil@clera.com
authors: Philip
authors: P
authors: Seeman
authors: Kenichi
authors: K
authors: Tokita
authors: Mitsuyuki
authors: M
authors: Matsumoto
authors: Ayako
authors: A
authors: Matsuo
authors: Masao
authors: M
authors: Sasamata
authors: Keiji
authors: K
authors: Miyata
mesh_terms: D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects*; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D016466:CHO Cells; D003001:Cloning, Molecular / Q000379:methods; D006224:Cricetinae; D003412:Cricetulus; D004298:Dopamine / Q000378:metabolism* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions / Q000502:physiology; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism; D008297:Male; D010880:Piperidines / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects; D011868:Radioisotopes / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D014162:Transfection / Q000379:methods; D010837:Vitamin K 1 / Q000031:analogs & derivatives / Q000378:metabolism
chemical_list: C510195:2-phytyl-1,4-naphthoquinone; D010880:Piperidines; D011868:Radioisotopes; D017448:Receptors, Dopamine D2; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D010837:Vitamin K 1; C483720:pridopidine; D004298:Dopamine